| NCT07141329 | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | RECRUITING | PHASE3 | 2025-07-30 | 2027-12-31 | 2027-12-31 |
| NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures | RECRUITING | PHASE2 | 2024-12-30 | 2026-10 | 2026-10 |
| NCT06185985 | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms | ACTIVE_NOT_RECRUITING | PHASE4 | 2024-03-28 | 2025-01 | 2025-01 |
| NCT04781140 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | RECRUITING | PHASE4 | 2024-03-19 | 2025-12 | 2025-12 |
| NCT06259331 | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women | COMPLETED | PHASE4 | 2023-05-23 | 2023-09-20 | 2023-09-20 |
| NCT05645432 | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus | COMPLETED | PHASE2 | 2023-05-10 | 2023-11-21 | 2023-11-21 |
| NCT05518578 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | UNKNOWN | PHASE2 | 2023-02-07 | 2025-01 | 2024-10 |
| NCT05619692 | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | COMPLETED | PHASE2 | 2022-11-29 | 2024-07-09 | 2024-06-05 |
| NCT05318937 | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | COMPLETED | PHASE2 | 2022-06-06 | 2024-02-23 | 2024-01-17 |
| NCT05358821 | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | COMPLETED | PHASE2 | 2022-05-26 | 2024-04-10 | 2024-02-29 |
| NCT05107128 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | COMPLETED | PHASE2 | 2022-01-26 | 2024-10-03 | 2024-09-04 |
| NCT04815967 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity | UNKNOWN | PHASE2, PHASE3 | 2021-11-16 | 2024-07-01 | 2023-07-01 |
| NCT05384977 | Mass Balance Study of NV-5138 in Healthy Male Subjects | COMPLETED | PHASE1 | 2021-11-11 | 2021-12-09 | 2021-12-09 |
| NCT05097079 | Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects | WITHDRAWN | PHASE3 | 2021-11 | 2023-05 | 2023-05 |
| NCT05102552 | Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects | COMPLETED | EARLY_PHASE1 | 2021-10-19 | 2022-08-15 | 2022-03-25 |
| NCT05059600 | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting | COMPLETED | PHASE4 | 2021-10-08 | 2022-07-14 | 2022-07-14 |
| NCT05049343 | Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants | COMPLETED | PHASE1 | 2021-09-21 | 2021-12-03 | 2021-11-20 |
| NCT04786990 | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD | COMPLETED | PHASE4 | 2021-07-27 | 2023-07-26 | 2023-05-23 |
| NCT04602624 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | COMPLETED | PHASE2 | 2020-12-07 | 2021-09-28 | 2021-09-28 |
| NCT04476017 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) | COMPLETED | PHASE2 | 2020-07-31 | 2022-03-25 | 2022-03-25 |
| NCT04050293 | Therapy for Migraine Prevention in Children 6-11 Years of Age | TERMINATED | PHASE4 | 2020-07-14 | 2024-05-29 | 2024-05-29 |
| NCT04143217 | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | COMPLETED | PHASE3 | 2020-01-23 | 2022-12-14 | 2022-07-26 |
| NCT04099667 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity | UNKNOWN | PHASE2, PHASE3 | 2019-12-17 | 2024-07 | 2023-04 |
| NCT04016779 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | COMPLETED | PHASE3 | 2019-11-20 | 2020-10-10 | 2020-10-10 |
| NCT04016792 | Classroom Study of SPN-812 in Children With ADHD | WITHDRAWN | PHASE3 | 2019-08 | 2020-11 | 2020-09 |
| NCT03638466 | Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD | TERMINATED | PHASE2 | 2019-05-30 | 2019-11-07 | 2019-11-07 |
| NCT03787758 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | COMPLETED | PHASE1 | 2019-02-28 | 2019-10-07 | 2019-10-07 |
| NCT03844906 | A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects | COMPLETED | PHASE1 | 2018-12-27 | 2019-04-01 | 2019-03-18 |
| NCT03770780 | A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects | COMPLETED | PHASE1 | 2018-11-12 | 2019-03-22 | 2019-03-08 |
| NCT03771586 | A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects | COMPLETED | PHASE1 | 2018-09-24 | 2019-01-02 | 2018-12-17 |
| NCT03665038 | A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) | COMPLETED | PHASE3 | 2018-09-07 | 2021-01-08 | 2021-01-08 |
| NCT03597503 | Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment | TERMINATED | PHASE3 | 2018-07-31 | 2020-01-22 | 2020-01-22 |
| NCT03474770 | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-04-10 | 2026-12-30 | 2026-12-30 |
| NCT03247556 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD | COMPLETED | PHASE3 | 2017-11-20 | 2019-02-14 | 2019-02-14 |
| NCT03247517 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD | COMPLETED | PHASE3 | 2017-11-02 | 2018-10-17 | 2018-10-17 |
| NCT03247543 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD | COMPLETED | PHASE3 | 2017-10-31 | 2018-10-17 | 2018-10-17 |
| NCT03247530 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD | COMPLETED | PHASE3 | 2017-10-20 | 2018-09-12 | 2018-09-12 |
| NCT03156439 | Bioavailability, Safety, and Tolerability of BIS-001 ER | COMPLETED | PHASE1 | 2017-05-22 | 2017-09-30 | 2017-09-30 |
| NCT02942017 | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C) | COMPLETED | PHASE3 | 2016-07 | 2017-10-11 | 2017-09-17 |
| NCT02691182 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) | TERMINATED | PHASE3 | 2016-04 | 2021-05 | 2021-05 |
| NCT02618434 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) | COMPLETED | PHASE3 | 2016-02-16 | 2020-02-14 | 2019-11-15 |
| NCT02736656 | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-02-02 | 2026-09 | 2026-09 |
| NCT02633527 | Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD | COMPLETED | PHASE2 | 2016-02-01 | 2016-07-25 | 2016-07-25 |
| NCT02618408 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) | COMPLETED | PHASE3 | 2016-01-25 | 2019-10-24 | 2019-09-04 |
| NCT02549573 | Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® | TERMINATED | PHASE4 | 2016-01 | 2016-12 | 2016-12 |
| NCT02614547 | A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression | COMPLETED | PHASE2 | 2015-12-15 | 2016-06-22 | 2016-06-22 |
| NCT02610868 | Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults | COMPLETED | PHASE3 | 2015-10 | 2017-06 | 2017-06 |
| NCT02339064 | Infusion of Apomorphine: Long-term Safety Study | ACTIVE_NOT_RECRUITING | PHASE3 | 2015-02 | 2025-12 | 2018-12 |
| NCT02285504 | Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression | COMPLETED | PHASE2 | 2015-01-07 | 2015-06-05 | 2015-06-05 |
| NCT02052739 | Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus | COMPLETED | PHASE1, PHASE2 | 2014-03-21 | 2015-05-03 | 2015-05-03 |
| NCT01994109 | Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects | COMPLETED | PHASE3 | 2013-11 | 2017-01 | 2016-01 |
| NCT02023606 | Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M | COMPLETED | PHASE1 | 2013-11 | 2013-12 | 2013-12 |
| NCT01770145 | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) | COMPLETED | PHASE4 | 2012-12 | 2014-04 | 2014-04 |
| NCT01416064 | Open-Label, Extension Study to 810P202 | COMPLETED | PHASE2 | 2011-09 | 2013-02 | 2013-01 |
| NCT01364662 | A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2011-06 | 2012-10 | 2012-10 |
| NCT01284530 | Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy | COMPLETED | PHASE1, PHASE2 | 2011-01 | 2012-06 | 2012-06 |
| NCT01107496 | Evaluation of Immediate-Release Viloxazine in Adults With ADHD | COMPLETED | PHASE1, PHASE2 | 2010-06 | 2010-12 | 2010-12 |
| NCT01114854 | A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM) | COMPLETED | PHASE1 | 2010-06 | 2011-01 | 2010-12 |
| NCT00918047 | Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients | COMPLETED | PHASE1 | 2009-06 | 2010-11 | 2010-07 |
| NCT00908349 | Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy | COMPLETED | PHASE3 | 2009-06 | 2011-11 | 2011-11 |
| NCT00772603 | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures | COMPLETED | PHASE3 | 2008-11 | 2010-11 | 2010-04 |
| NCT00626236 | Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems | COMPLETED | PHASE2 | 2008-10-21 | 2009-09-23 | 2009-09-23 |